Medtronic plc announced primary endpoint results from the SPYRAL AFFIRM post-approval study of the Symplicity Spyral renal denervation (RDN) system. The study showed statistically significant and clinically meaningful… read more.
Exercise should be prescribed as a foundational component of cardiovascular disease (CVD) prevention and treatment, according to a new American College of Cardiology Scientific Statement published today in… read more.
An estimated 6,000 women enter menopause every day in the United States, according to the National Institutes of Health. Yet many are surprised to learn that the years… read more.
Abbott announced FDA approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities through the CardioGuide HF App. For the first time, care teams can… read more.
Johnson & Johnson announced the U.S. launch of its Shockwave C2 Aero Fly Coronary IVL Catheter designed to treat a broad range of calcified coronary artery lesions in… read more.
Effective management of high blood pressure could prevent more than 518,000 annual deaths from cardiovascular disease around the world, according to preliminary research presented at the American Heart… read more.
Idorsia shared positive findings from two new analyses of the pivotal Phase 3 PRECISION study of aprocitentan in patients with resistant hypertension, at the American Heart Association Hypertension… read more.
Eli Lilly and Company announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron) compared to titrated insulin glargine in adults… read more.
Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive… read more.
Eli Lilly and Company announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and… read more.
Novo Nordisk announced new retrospective real-world evidence in adults with type 2 diabetes treated with once-weekly semaglutide injection 1 mg. In the analysis, adults who escalated to semaglutide… read more.
Intensive efforts to maintain low blood pressure can lower the incidence of dementia, according to a trial in rural China which was delivered by non-physician healthcare providers. Headline… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
